Souffle Therapeutics is a biotechnology company aimed at advancing the next generation of therapies to help people live healthier lives. The Company's proprietary product engine, REMEDY (Receptor Mediated Delivery), enables cell-specific extra-hepatic delivery of oligonucleotide therapies across multiple cell types to enable the development of potent, safe and durable therapies across a range of diseases. Souffle's initial programs target striated muscle (both skeletal muscle and cardiomyocytes) to help people living with various muscle dystrophies and heart failure with reduced ejection fraction (HFrEF). The Company is also advancing a program to address muscle and metabolic disorders, and its product engine is enabling development of novel therapies for other cell types and tissues.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/19/26	$135,000,000	Series B	Amgen Ventures ARCH Venture Partners Balyasny Asset Management BB Biotech Ventures Bessemer Venture Partners Breyer Capital Fidelity Management & Research Company Invus Group Janus Henderson Investors Juvia Group Leaps by Bayer Polaris Partners Safar Partners TAS Partners TCG Crossover Temasek Vida Ventures	undisclosed